Ryan Savitz Biography and Net Worth

Mr. Savitz brings over a decade of experience providing strategic and financial advice to life sciences companies. He most recently served as Managing Director in Citigroup’s Healthcare Investment Banking division, where he focused on advising biopharma companies on private and public capital raising, partnering, and mergers and acquisitions. Prior to becoming Managing Director, he held positions of increasing responsibility all within the Healthcare Investment Banking division at Citigroup. Mr. Savitz received his Bachelor of Science in Finance from the Pennsylvania State University.

What is Ryan Savitz's net worth?: The estimated net worth of Ryan Savitz is at least $3.25 million as of July 9th, 2026. Savitz owns 31,249 shares of Dianthus Therapeutics stock worth more than $3,252,708 as of July 30th. This net worth evaluation does not reflect any other assets that Savitz may own. Learn More about Ryan Savitz's net worth.
How do I contact Ryan Savitz?: The corporate mailing address for Savitz and other Dianthus Therapeutics executives is 203 Crescent Street, Building 17 Suite 102B, Waltham, MA 02453, United States, . Dianthus Therapeutics can also be reached via phone at 857-242-0170 and via email at [email protected]. Learn More on Ryan Savitz's contact information.
Has Ryan Savitz been buying or selling shares of Dianthus Therapeutics?: During the past quarter, Ryan Savitz has sold $3,157,086.47 of Dianthus Therapeutics stock. Most recently, Ryan Savitz sold 31,249 shares of the business's stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $101.03, for a transaction totalling $3,157,086.47. Following the completion of the sale, the executive vice president now directly owns 31,249 shares of the company's stock, valued at $3,157,086.47. Learn More on Ryan Savitz's trading history.
Who are Dianthus Therapeutics' active insiders?: Dianthus Therapeutics' insider roster includes Edward Carr (Chief Accounting Officer), Marino Garcia (President & Chief Executive Officer, Board Member), Simrat Randhawa (Insider), Ryan Savitz (CFO), and Adam Veness (SVP). Learn More on Dianthus Therapeutics' active insiders.
Are insiders buying or selling shares of Dianthus Therapeutics?: During the last twelve months, insiders at the sold shares 12 times. They sold a total of 647,338 shares worth more than $43,532,417.64. The most recent insider tranaction occured on July, 9th when EVP Ryan Savitz sold 31,249 shares worth more than $3,157,086.47. Insiders at Dianthus Therapeutics own 3.0% of the company. Learn More about insider trades at Dianthus Therapeutics.
Information on this page was last updated on 7/9/2026.

Ryan Savitz Insider Trading History at Dianthus Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/9/2026	Sell	31,249	$101.03	$3,157,086.47	31,249
4/9/2026	Sell	8,224	$89.84	$738,844.16	8,224
3/31/2026	Sell	114,367	$83.00	$9,492,461.00
12/4/2025	Sell	20,000	$45.18	$903,600.00
9/9/2025	Sell	20,000	$35.00	$700,000.00

Ryan Savitz Buying and Selling Activity at Dianthus Therapeutics

Dianthus Therapeutics Company Overview

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Today's Range

Now: $108.41

$104.10

$111.64

50 Day Range

MA: $91.76

$76.42

$105.72

2 Week Range

Now: $108.41

$18.08

$111.64

Volume

408,625 shs

Average Volume

977,427 shs

Market Capitalization

$5.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2